Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Yidawei** is a Chinese branded peritoneal dialysis solution family manufactured by Shijiazhuang No. 4 Pharmaceutical. It is marketed as lactate-buffered, glucose-containing peritoneal dialysis solution in 1.5%, 2.5%, and 4.25% glucose strengths, supplied in 2,000 mL dual-bag systems for intraperitoneal use. The solution supports peritoneal dialysis by creating concentration and osmotic gradients across the peritoneal membrane, facilitating removal of uremic solutes and excess fluid while helping maintain electrolyte and acid-base balance in patients with kidney failure. The product has Chinese drug approval numbers for its three glucose strengths and has been evaluated in a post-marketing study in adults undergoing continuous ambulatory peritoneal dialysis. ([sjzsiyao.com](https://www.sjzsiyao.com/product/187.html))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yidawei.